everyone to and X and I update activities and discuss background afternoon, some my we'll of an On our reasons and our Good with by begin XXXX trial, then update Phase sharing fourth why today's call We'll our R&D begin on decided call. Vital I'll welcome clinical the publications. to Therapies'. quarter join XXX
questions. fourth review and We quarter up finish will than we’ll financial results our with
to I’d know job, like don’t So by Therapies. join an me discussing background. already, of you to who my briefly with begin great company I left those for a exciting Vital
about to I than direct colleagues I future, XX% was former a than was Genentech, Prior started commercialization, the bright best $XXX Commercial friends and R&D, grew years senior Scios, molecule particular commercial launches. looking global responsibility been I screen hold company I I was have fortunate years. J&J, the in my carrier, by many course and to I roles wish that eventually Pharmaceuticals, there. billion in Officer met in global which my manufacturing carrier of in at and of Officer Ipsen. spent of spend the an Jazz the had I as I decided a When which that take to step XX my was bought many a Operating generated mind. at Chief and including next Chief When more over at my involved Tercica, XX had I during who for million company, leadership. as about for Jazz, carrier revenues, and where the to As in has bought I Jazz by Jazz, my tenure. $X.XX role the I opportunity started
for close positioned policy cell generation, and and long guidance specifically a is that was greatest screening well itself Century next years. and the I coming or the medical was XXst frameworks environment lived opportunities, and it of its clearly these the generation, from therapy gene thought approval therapy I in development I met in multiple commercialization, competitive unmet in and innovation something had believe be in maturing cell or this therefore to order is a After will strong for position gene demonstrated to pathways. Something the success, value. Vital therapies by as such I either next looking where Act, reviewing. that associated view see that's policy The approving Cures of is specifically regulatory therapy, been or opportunities in address of screen, need cell and and differentiated believe because me cell the other separated be establishment therapy, the we also for large maximize asset a and gene I with Therapies to that for it and gene late regulatory technical something address stages something new
arguably new greatest the therapy two gene and with approved place, therapy the field years, of trials the potential CAR-T excitement has amount and FDA gene a and and With products healthcare. the in it's cell product. in of clinical hundreds taking Just past
evaluate unique ready success. of design trial opportunities also the ELAD. the analysis Vital a already the regulatory to assets had truly subgroup This X BLA BLA With have of the enrolled timely extensive been to products approached pathway I've the right and my disciplined begun Technically on launching the therapy the From by medical dataset, over of favorable. commercialization on the [ph] XXX believe of and course technical from strong of commercialization we in has in these ELAD hit at experience approval. believe in is plan potential stage development, and results, trying of in is event be I highly that targeting time. quite XXX we'll trial to to of to place standpoint, running working Therapies' the the is for and rationale. in event indication Phase put a less ground be access the could the matter. late I cell commercialization the favorable right the positive in pivotal always new at anticipate opportunity the XXXX prior event a a of in results. eager of my the regulatory number an positive We've therapeutics. large learning I'm I've a use our with career based the probability and In stages
results. failure, As a trial acute the Europe be XX,XXX About liver treated ELAD critical an the event in in could of orphan that positive you could indication with U.S. and from potentially know address ELAD. in unmet need people suffer
indication EU. Our first the severe or alcoholic XX,XXX sAH in affects target patients and U.S. hepatitis the about
opportunities like post-surgical alcoholic liver Mushroom Beyond sAH poisoning. [ph] overdose failure, and we areas have in
want our only need have is a to in commitment, difficulty stage not to we real world commercial with impact We people first obvious that, suffering comparable Terry our update the rest thank to of to several predecessor, he's system to to disease. believe trial. two successful, the difficult liver of company. or been in an there one a endpoint. our else express years. during options would monotherapy Should leader you anyone now and very lead would long-term Therapies' his my for distinguish also look successful clinical opportunity why done very of company rest U.S. especially the for it large it's to in any to being ELAD we have turn of this is for support complex forms Vital follow hopefully either suggest been would Bottom-line, to in EU. for liver can you a I also the time. at explored From would enterprise. gratitude wonderful medical for positioned approach to bio-artificial in this thrilled from into passion see our XXX leader the development I outstanding And failure There efforts Terry a the In very field hard approaches Vital make China. their of believe there but has a hope considerable this early overall be arena. months, other really here are there competitive monotherapy hepatitis To that for like Therapies' and And Winters, the standpoint, us disease in them deepest behind the time. working in I I'll that need. and patients now Phase are related to survival long exciting this approach Despite a the my reasons is the my ELAD forward be I an be X address we knowledge believe in B believe point. for the this cellular appears there me I'm work. some no transform liver to where nature is failure to stages Vital at it to a unmet problem Board therapeutic to the acute others, -- we significant Therapies no well get of become with the without new in all the a Vital a at is
number and completing XXX finish enrollment of one sight. in is priority the now is the Our line
for open had XX time the subjects last of sites enrolled had last enrolment. of subjects in we sites on This of enrolled yesterday, we XX at update XX XXX As our year. with compares and October XXX
achieve lock. event-driven of recall, enroll at overall design you time the an study approximately incorporates that the of to flexibility As if the necessary provides events blended target XX data will subjects, XXX help to feature of total additional
statisticians, many who in study. Thomas as from Washington, rate including Fleming early XXXX event concluded including consultant data lock. first these of statistical the the original yield event blended Dr. the the XX the rate be year-end Fleming a know XXX FDA, approximately of to time planned predicted evaluated statistical you would Dr. the to experts the respected experts, the was University As consistent that of in events plan, quarter, and independent likely These the of the as of at observed data modeled with
As of the the we XXX endpoint result, the this insight the should patients. It of blinded will data was target that recommended primary enrollment no statisticians to the a and therefore analysis that study. original treatment retain arm provided used noted as in on be
XXX consistent of we on rate the We event what design expected appears that the the original and with pleased to trial. be based are
by statisticians. XXX period then days for our short will expect XXX to and of in enrolled, this period enroll us has be As results we from we last XXXX lock begins, likely the keeps of QX, a independent anticipate in month. we months to minimum which Once September. party on That a analyzed subject following a patient been XX data couple track follow-up the third top-line the result, database the the in to timeline to last continue report
short the maintain I'd XXX release the the with trial press being to enrolled trial, XXX no included in is all Before you their range to closely in learnings impressive clinical also criteria. my pull patient based. the participation. to based trial the only I afternoon's to of investigators, the and In to that the in methodically Therapies, design the a Joining patients this themselves including company reference which design is can characteristics line our we aligned table design conducted trial complex things observed to remain XXX take our fall the difficult and based the the the pivotal and met this XXX As execution continue off hospital deliberate within most trial Vital discipline to see the have applied from for required trial. of ensure contributed subjects congratulate was like in on cuts with experience trial We've subjects found study our which one the but all not XXX about the on study means was those in population thank base clinical of remains who to execution and those this their rigor
and publication trial A the our R&D provides results current delighted of is Long The progress March turning Timothy Journal with study. of the Lining. highlighted of the accompanying Silver XXX detailed entitled Morgan XXX we Healthcare this rationale for editorial to Now Transplantation. VA Potential in our the were clinical by see work And in to design of system Beach paper ELAD, the Dr. full the issue Liver the publications,
progress ELAD cell VTL of make we in analyzing relevant with This variety potential cells action. alcoholic in-vivo. cell to proteins been far a laboratory our hepatitis. from in the mechanism XXX survival we've samples under to types. so influencing and explore hypothesis clinical hypothesis the their other subjects of understanding looking these on by our has have the work to prior at for various work has maybe been led of mechanisms of in Most CXA studies which continue impact severe reported We release Recently that conditions based
show of can that related circulating to substances these to hoping in are We changes in level clinical improvement conditions. be
produced endothelial of [ph] in by showed VGEF-A cells. endothelia a procalcitonin and In increase shown samples, VTL while samples, have inflammation proteins, to to activity have our X, also treatment. on during focused that and dysfunction concentration CXA IL-XRa, ELAD other plasma treatment. fats the during same we far in soluble models So ELAD markers and including been marker increasing ferritin, of been shown in-vitro XXX proteins three subject the
results vivo findings. in-vitro Taken of to an suggestive are together, ELAD treatment in these the with response consistent
and X, Week ability of other This the -- continue in by upcoming presentations factors abstract These the Association has each of by and Study we and or stress Washington produced held titled, cell of through sponsored Paris, Clinical addition, at be will the to endothelial hepatocytes prevent the held cells, on XX, through for including, conference. in to EASL in be death cells subject Digestive scientific Relations the D.C. to work or Conference macrophages. associated In posters our available and Liver of VTL DDW Congress XXXX the April for CXA basis presentation study be by proteins International XX and Disease Presentations June European website, and close section conferences, X, XXXX oxidative and Investor formed to reduce under the Publications Liver
apoptosis. characteristics a potential these encouraging data pathological severe of CXA While and as we preliminary, liver key an hepatitis they are regeneration information, the VTL provide into to alcoholic insight for cells have believe impaired impact the such on significant
like our profusion on provide would a I liver program. research to Lastly, update brief
the potentially financial to our of on demonstrate utilize reporting cells turn to forward in discussion generated Drexel promise We program to cells of fourth the a by I’ll we Birmingham of vivo these organs potential and a increasing Mike shown livers. VTL agreement Preliminary this proteins, the over number marginal for VTL UK and by CXA pursue ex future. in proteins for results and more are of positive the possibly available We the extended for have to definitive and with call results. livers model, our improve of continuing thereby research on Philadelphia the in working generated we look University more to have condition the are quarter collaboration transplantation. effects now CXA donor marginal University
